Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
Division of Hematology, Oncology, and Stem Cell Transplant, Rush University Medical Center, Chicago, Illinois, USA.
BMJ Case Rep. 2021 Sep 21;14(9):e245350. doi: 10.1136/bcr-2021-245350.
We present a unique case of a patient with a long-standing history of indolent chronic lymphocytic leukaemia (CLL) who suddenly developed autoimmune haemolytic anaemia after starting immune checkpoint inhibitor therapy for bladder cancer. He had no clear indication to start CLL-directed treatment based on current clinical practice guidelines; however, targeted treatment of CLL with ibrutinib proved to be effective in treating the haemolytic anaemia.
我们报告了一例独特的病例，该患者患有慢性惰性淋巴细胞白血病（CLL）多年，在开始膀胱癌免疫检查点抑制剂治疗后突然发生自身免疫性溶血性贫血。根据当前的临床实践指南，他没有明确的指征开始针对 CLL 的治疗；然而，用伊布替尼对 CLL 进行靶向治疗证明对治疗溶血性贫血有效。
